Cancer Care

 

 
Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy, Phase III
Principal Investigator (?)
Study Number
C99904
Summary
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy
may fight prostate cancer by reducing the production of androgens. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. It is not yet known whether hormone therapy plus mitoxantrone and prednisone is more
effective than hormone therapy alone for prostate cancer.

PURPOSE: This randomized phase III trial is studying hormone therapy, mitoxantrone, and
prednisone to see how well they work compared to hormone therapy alone in treating patients
who have undergone radical prostatectomy for prostate cancer.
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)

Southwestern Vermont

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.